Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2020 07:00 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma

AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
January 08, 2020 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

AUSTIN, Texas, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s...
December 19, 2019 07:00 ET | Source: Molecular Templates, Inc.

Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s...
December 09, 2019 10:00 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s...
November 26, 2019 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates to Present at Two December Investor Conferences

AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s...
November 21, 2019 07:00 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...
November 20, 2019 16:01 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Announces Proposed Public Equity Offering

AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and...
November 18, 2019 07:00 ET | Source: Molecular Templates, Inc.

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

-Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. ...
November 12, 2019 17:00 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the...
November 07, 2019 16:27 ET | Source: Molecular Templates, Inc.

Molecular Templates Hosting Analyst & Investor Meeting

AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s...